Appendix Table 4.
Mean Change in Hemoglobin Level in Participants With Baseline Anemia Who Received Placebo or Canakinumab
| Time Point | Placebo | Canakinumab | |||
|---|---|---|---|---|---|
| 50 mg | 150 mg | 300 mg | All Doses | ||
| 3 months | |||||
| Participants, n | 408 | 242 | 280 | 291 | 813 |
| Mean change in hemoglobin level (SD), g/L | 3.82 (11.02) | 6.45 (10.19) | 7.50 (11.36) | 7.14 (10.95) | 7.06 (10.8) |
| P value | Reference | <0.001 | <0.001 | <0.001 | <0.001 |
| 6 months | |||||
| Participants, n | 385 | 238 | 269 | 280 | 787 |
| Mean change in hemoglobin level (SD), g/L | 5.65 (12.89) | 6.63 (11.85) | 8.27 (12.43) | 8.05 (11.93) | 7.70 (12.08) |
| P value | Reference | 0.116 | 0.001 | 0.005 | 0.001 |
| 9 months | |||||
| Participants, n | 380 | 235 | 258 | 266 | 759 |
| Mean change in hemoglobin level (SD), g/L | 6.15 (13.75) | 7.97 (12.74) | 8.29 (13.53) | 8.96 (13.28) | 8.43 (13.19) |
| P value | Reference | 0.011 | 0.016 | 0.003 | 0.001 |
| 12 months | |||||
| Participants, n | 372 | 232 | 249 | 261 | 742 |
| Mean change in hemoglobin level (SD), g/L | 7.03 (13.55) | 9.49 (14.23) | 8.91 (13.20) | 9.76 (14.16) | 9.39 (13.85) |
| P value | Reference | 0.008 | 0.023 | 0.007 | 0.001 |
| 24 months | |||||
| Participants, n | 331 | 208 | 238 | 233 | 679 |
| Mean change in hemoglobin level (SD), g/L | 7.80 (14.73) | 10.80 (14.49) | 10.90 (14.60) | 12.20 (13.74) | 11.30 (14.27) |
| P value | Reference | 0.006 | 0.002 | <0.001 | <0.001 |
| 36 months | |||||
| Participants, n | 306 | 191 | 221 | 220 | 632 |
| Mean change in hemoglobin level (SD), g/L | 7.31 (14.80) | 10.37 (15.85) | 10.80 (13.83) | 11.73 (15.68) | 10.99 (15.10) |
| P value | Reference | 0.019 | 0.001 | 0.002 | <0.001 |
| 48 months | |||||
| Participants, n | 189 | 112 | 141 | 140 | 393 |
| Mean change in hemoglobin level (SD), g/L | 8.90 (15.53) | 11.90 (18.17) | 10.30 (14.10) | 10.00 (15.67) | 10.60 (15.88) |
| P value | Reference | 0.149 | 0.186 | 0.42 | 0.131 |